This page shows the latest PCSK9 inhibitors news and features for those working in and with pharma, biotech and healthcare.
It will launch into a cholesterol market that was static for years and remains dominated by statins, but has seen a couple of new entrants – two injectable PCSK9 inhibitors from Amgen ... and Sanofi/Regeneron – and could see a launch later this year
A report from Bloomberg also suggests that other buyers are interested in MedCo as it prepares to file for approval of inclisiran – a gene-silencing drug targeting PCSK9 that can reduce ... If approved, inclisiran could pose a major challenge to
drugs. New therapies like Novartis’ heart failure therapy Entresto (sacubitril/valsartan) and cholesterol-lowering PCSK9 inhibitors from Amgen and Sanofi/Regeneron have re-injected growth into the market, although they have
If approved, inclisiran will compete most closely with two antibody-based PCSK9 inhibitors – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – but will offer efficacy that is at least ... Alnylam-partnered inclisiran is
The small, interfering RNA (siRNA) drug – which works by blocking the synthesis of PCSK9 in the liver – was being tested in patients with atherosclerotic cardiovascular disease (ASCVD) who were unable to ... That is a much less frequent dosing
Despite patients already taking lipid-lowering treatments, such as statins and PCSK9 inhibitors, their levels of cholesterol remained dangerously high prior to enrolment in the study. ... Regeneron and partner Sanofi have another approved
More from news
Approximately 1 fully matching, plus 40 partially matching documents found.
We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...